Chronic Pain News and Research

RSS

Predictors for pain after breast cancer surgery unveiled

Researchers have identified that chronic preoperative pain, axillary surgery, and psychologic robustness significantly predict acute pain outcomes after breast cancer surgery.

5 Sep 2012

Roundup: Texas probes Xerox in Medicaid overbilling; Miss. abortion clinic fights to stay open

Texas authorities are investigating whether Xerox Corp. played a role in allowing dentists to allegedly overbill the state's Medicaid system by millions of dollars.

5 Sep 2012

Young doctors seek to alter practice of medicine; Medical schools push training in addiction

The Associated Press examines how tech-savy young doctors are changing medicine, and KHN looks at efforts to train doctors to recognize how addictions complicate other health problems.

5 Sep 2012

First Edition: September 4, 2012

Today's early morning highlights from the major news organizations, including previews of the Democratic convention and a New York Times analysis of how the Obama and Romney campaigns vary on Medicaid policy.

4 Sep 2012

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

Non-pain-related factors predict long-term opioid use after surgery

Non-pain-related factors—including previous use of pain medications, high perceived risk of addiction, and symptoms of depression—increase the risk of continuing to use strong pain-relieving drugs several months after surgery, reports a study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

31 Aug 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

MRC awards grant to design new drug for treatment of chronic pain

Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded -1.4 million to design a new drug for the treatment of chronic pain.

24 Aug 2012

Arthritis patients prioritize lifestyle intervention research

Most patients believe that research into joint pain should focus on self-management and lifestyle modifications, suggests a UK survey of older individuals with self-reported joint pain.

20 Aug 2012

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).

16 Aug 2012

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

The American Pain Society (APS) announced today it is accepting applications for research grants from the newly established Sharon S. Keller Chronic Pain Research Program.

16 Aug 2012

Kessler Foundation investigates Ekso's new capabilities for autonomous use by people with SCI

Kessler Foundation has begun testing the upgraded Ekso in individuals unable to walk due to spinal cord injury. Ekso, a wearable, battery-powered robotic exoskeletal device, has been undergoing clinical investigation at Kessler since October 2011, when the research team received the second commercial unit distributed by Ekso Bionics.

15 Aug 2012

Doctors may underestimate importance of small set of risks that vex patients

Most informed consent disputes involve disagreements about who said what and when, not stand-offs over whether a particular risk ought to have been disclosed. But doctors may "routinely underestimate the importance of a small set of risks that vex patients" according to international experts writing in this week's PLOS Medicine.

10 Aug 2012

Doctors sometimes fail to warn patients of particular risks before treatment

Australian doctors sometimes fail to warn patients of risks that could affect the patient's quality of life before providing treatment or surgery, a new study led by University of Melbourne researchers has shown.

9 Aug 2012

Chronic Pain News and Research

Predictors for pain after breast cancer surgery unveiled

Roundup: Texas probes Xerox in Medicaid overbilling; Miss. abortion clinic fights to stay open

Young doctors seek to alter practice of medicine; Medical schools push training in addiction

First Edition: September 4, 2012

Potassium-channel autoimmunity linked to chronic pain

Non-pain-related factors predict long-term opioid use after surgery

Chronic nerve pain: an interview with Professor Sally Lawson

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

MRC awards grant to design new drug for treatment of chronic pain

Arthritis patients prioritize lifestyle intervention research

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

Kessler Foundation investigates Ekso's new capabilities for autonomous use by people with SCI

Doctors may underestimate importance of small set of risks that vex patients

Doctors sometimes fail to warn patients of particular risks before treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News